Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. - Wikidata - wikimedia - TriplyDB

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.

http://www.wikidata.org/entity/Q37847070

about

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53 Anti-angiogenic drugs currently in Phase II clinical trials for gynecological cancer treatment.Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model.Tyrosine kinase inhibitor BIBF1000 does not hamper right ventricular pressure adaptation in rats.

P2860

Q26743407-72B9940B-5F0C-46FF-B690-7D67C35CC9E2 Q27026936-C7B93FDE-135C-4E86-A1AA-3D63AD34E9C4 Q33563488-BC09F6E8-9AB6-4BB9-AC19-76CC5DAE24B7 Q36957621-38F40CB7-11D4-4910-87CC-AB4A1ABC7D22 Q37411955-B7521354-12D6-47E8-B9EE-FA7C1A6197A0 Q38115596-C1C205C4-30E8-433E-ACA0-B3C569FCE235 Q43989660-5126F313-D859-4D08-818E-54D4F677E21F Q48144212-8A072002-8984-4D5D-A7D1-AFCB63632442 Q51501927-D9EC4882-9BCF-4DF1-828F-43275CF4F069

P2860

Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor.

http://www.wikidata.org/entity/Q37847070

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 February 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@en

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@nl

type

label

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@en

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@nl

prefLabel

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@en

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@nl

P1433

Q37847070-51F718A5-DC11-4B5A-8DCB-33F8E7FD6D21

P1476

Q37847070-94BD9BCB-0A8C-4B8D-998D-79205574210F

P2093

Q37847070-03538D41-B51B-4C42-BDD3-4A0B72BD909C

Q37847070-68A7FE1C-B516-4620-87CA-7CFDE79FCC50

Q37847070-C0FFAEB0-7EAF-48FF-94E8-66128059A77D

P2860

Q37847070-0009F459-5A17-49BD-B5D0-914DB97884CE

Q37847070-0F0E5F59-09F5-415E-8A3C-B37B72D49695

Q37847070-1683C445-4657-4A0B-B5C8-670456D5E2CE

Q37847070-1B962444-8D5D-466D-B9DC-698A98322D8E

Q37847070-2CCB0AAF-66F1-4224-83AE-29CE28CD949D

Q37847070-3037B095-5266-41B2-BF7E-FF973C36EA32

Q37847070-314F8671-1263-4E2A-9907-61B721A7B758

Q37847070-32405DC1-2B0F-466B-9DBF-F8EA72645145

Q37847070-35715617-9F36-4EC5-8FC4-11349EE6446D

Q37847070-49E8E5E8-3DFA-4BBF-9E03-60E3BF560905

P2888

Q37847070-99F8C048-C87F-4AAC-8164-066ABB927C83

P304

Q37847070-C824D58A-B7B6-42BA-802F-196C2E1D16AF

P31

Q37847070-2770BD0D-38AC-4297-A57A-3099492254CF

P356

Q37847070-9AA41E25-F787-4055-B905-AC24C5474A25

P433

Q37847070-9222878D-23A4-4DCC-AF83-9993CA563E29

P478

Q37847070-0042A9EE-5C65-4A8F-9B2D-9A2127575BA6

P577

Q37847070-D37E7B09-7842-4248-8A90-E2129B1DEA28

P698

Q37847070-8BD1FAA7-1B3D-40DD-A220-CD9A94FACC1F

P356

S10637-011-9644-2

P1433

Investigational New Drugs

P1476

Targeting angiogenesis from mu ...... triple angiokinase inhibitor.

@en

P2093

Edgardo S Santos

http://www.w3.org/2001/XMLSchema#string

Jorge E Gomez

http://www.w3.org/2001/XMLSchema#string

Luis E Raez

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

Angiogenesis in cancer and other diseases

Sorafenib in advanced hepatocellular carcinoma

R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

P2888

s10637-011-9644-2

P304

1261-1269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-011-9644-2

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21350804

http://www.w3.org/2001/XMLSchema#string